International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
Kian Fan Chung, Sally E Wenzel, Jan L Brozek...
https://pubmed.ncbi.nlm.nih.gov/24337046/Actively Recruiting
Led by University of California, San Diego · Updated on 2024-08-19
120
Participants Needed
3
Research Sites
30 weeks
Total Duration
Researchers are investigating how two approved biologic therapies, Dupilumab and Benralizumab, work for adults with moderate to severe asthma. The study aims to understand each patients unique response to these treatments by using genomic and biological measurements from blood and tissue samples. This approach could improve how asthma treatments are personalized and help predict which patients will benefit the most. The study includes two treatment options given in a random order Dupilumab, which is given as an initial 600 mg dose via two injections followed by 300 mg every two weeks, and Benralizumab, given as a 30 mg injection every four weeks. Participants may also choose to use Symbicort as their controller medication. These treatments are part of standard care and not experimental drugs. The study involves detailed evaluations before and after each therapy, including advanced genetic testing. Participants will be closely monitored over about 60 weeks with regular assessments of asthma control, quality of life, lung function, and biological responses to the treatments. Researchers will use questionnaires and lung tests throughout the study to track changes and predict treatment outcomes. Safety will be monitored continuously to ensure participant well-being during the study period.
CONDITIONS
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
C
Clinical Trial Operations and Data Management Specialist UA-DCC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Diego
Lead Sponsor
Mayo Clinic
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Dupilumab (Interleukin-4 receptor inhibitor) | Benralizumab (Interleukin-5 receptor inhibitor) |
|---|---|---|
| What it is | Dupilumab is a monoclonal antibody targeting the interleukin-4 receptor, used for severe asthma as an add-on to standard controller therapy. | Benralizumab is a monoclonal antibody targeting the interleukin-5 receptor, used for severe asthma as an add-on to standard controller therapy. |
| Role in trial | Dupilumab is assigned as one crossover condition; each participant receives it during one period to directly compare response vs Benralizumab. | Benralizumab is assigned as the alternate crossover condition; every participant also receives it for within-participant comparison. |
| Primary use | Used for add-on biologic therapy in moderate to severe asthma where control is suboptimal; intended to improve exacerbation rates and control. | Used as an add-on biologic in moderate to severe asthma with ongoing symptoms; intended to improve asthma control and reduce exacerbations. |
| How it is given | Dupilumab is administered as a 600 mg initial subcutaneous injection (two sites), followed by 300 mg injections every two weeks. Participants may self-administer after training. | Benralizumab is administered as a subcutaneous injection every four weeks. Participants may self-administer after receiving proper training. |
| Evidence status | Dupilumab effectiveness and safety for severe asthma are supported by clinical trial evidence and guideline endorsement. Comparative effectiveness vs Benralizumab remains under investigation in current research. | Benralizumab is supported by published clinical trials and guideline endorsement for severe asthma. Direct head-to-head comparison with Dupilumab is ongoing in this crossover study design. |
| Important limitations | The trial does not include a placebo or non-biologic comparator; only within-patient comparison is possible. Real-world differences between Dupilumab and Benralizumab will rely on ongoing research for head-to-head outcomes. | No standard care or placebo group is present. Only patients eligible for biologics are studied, so comparisons with other asthma therapies remain outside trial scope. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 16 weeks per biologic
Participants receive treatment with two different biologic therapies, Dupilumab and Benralizumab, in a random order to assess their asthma outcomes and therapeutic responses.
Biweekly visits for Dupilumab and monthly visits for Benralizumab during treatment periods
Duration - Up to 60 weeks
Participants are monitored for asthma control, quality of life, lung function, and asthma-related events after treatment completion.
Periodic visits throughout study completion
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kian Fan Chung, Sally E Wenzel, Jan L Brozek...
https://pubmed.ncbi.nlm.nih.gov/24337046/Anne L Fuhlbrigge, Thomas Bengtsson, Stefan Peterson...
https://pubmed.ncbi.nlm.nih.gov/28583396/Wendy C Moore, Deborah A Meyers, Sally E Wenzel...
https://pubmed.ncbi.nlm.nih.gov/19892860/Eugene R Bleecker, Andrew N Menzies-Gow, David B Price...
https://pubmed.ncbi.nlm.nih.gov/31525297/Allan L Coates, Jack Wanger, Donald W Cockcroft...
https://pubmed.ncbi.nlm.nih.gov/28461290/Sunita Sharma, Alvin T Kho, Divya Chhabra...
https://pubmed.ncbi.nlm.nih.gov/25192440/Alberto Papi, Christopher Brightling, Søren E Pedersen...
https://pubmed.ncbi.nlm.nih.gov/29273246/Fernando Holguin, Juan Carlos Cardet, Kian Fan Chung...
https://pubmed.ncbi.nlm.nih.gov/31558662/Ryan K Nelson, Andrew Bush, Jeffrey Stokes...
https://pubmed.ncbi.nlm.nih.gov/31786254/Anne Fuhlbrigge, David Peden, Andrea J Apter...
https://pubmed.ncbi.nlm.nih.gov/22386508/University of California, San Diego
Lead Sponsor
Mayo Clinic
Collaborating Sponsor